Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,873,864 shares, a decline of 6.2% from the November 15th total of 1,998,494 shares. Based on an average trading volume of 173,935 shares, the short-interest ratio is currently 10.8 days. Approximately 2.6% of the company’s stock are short sold.
An institutional investor recently bought a new position in Matinas BioPharma stock. Yellowstone Partners LLC acquired a new stake in shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 143,914 shares of the company’s stock, valued at approximately $190,000. Yellowstone Partners LLC owned 0.16% of Matinas BioPharma as of its most recent SEC filing.
Separately, ValuEngine downgraded shares of Matinas BioPharma from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th.
Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its earnings results on Wednesday, November 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.05 million. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%.
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.